Alligator Bioscience expands management team
Appointment of Chief Medical Officer and VP Discovery Lund, Sweden, 4 December 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biot ...
Alligator Bioscience AB presents at Redeye Life Science Seminar 24 November 2017
Lund, Sweden, 21 November 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceu ...
Nomination Committee appointed in respect of AGM 2018 in Alligator Bioscience AB
Lund, Sweden, 13 November, 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmace ...
Results from Alligator Bioscience’s clinical phase I study support further clinical development of ADC-1013
Lund, Sweden, 7 November 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceut ...
Alligator Bioscience AB Interim Report January-September 2017
Three important collaborations in place. Results in November from ADC-1013 clinical phase I study. Significant events, July-September • Apte ...
Alligator Bioscience Aptevo Therapeutics: Tumor antigen 5T4 associated with many forms of solid tumors identified as the second target for ALG.APV-527
ALG.APV-527 – A novel bispecific antibody candidate being developed by Alligator Bioscience and Aptevo Therapeutics. Engineered to Eng ...
Alligator Bioscience to present ADC-1013 intratumoral clinical phase I study results at SITC in November 2017
Lund, Sweden, September 21, 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmac ...
Alligator Bioscience signs immunotherapy research collaboration agreement for 4-1BB
Research team to be led by Professor Ignacio Melero, Center for Applied Medical Research (CIMA) and Clínica Universidad de Navarra, Spain Lu ...
Alligator Bioscience AB (Nasdaq Stockholm; ATORX) Interim report January – June 2017
“We have advanced our project pipeline significantly during the second quarter. The immuno-oncology antibody ATOR-1017 moved into pre-clinic ...